Cai Ying-Ying, Zou Shao-Zhou, Fan Cun-Xia, Wu Chun-Yan, Fang Shu, Li Ping, Xue Yao-Ming, Guan Mei-Ping
Department of Endocrinology and Metabolism, Nanfang Hospital, Southern Medical University, Guangzhou 510150, China.E-mail:
Nan Fang Yi Ke Da Xue Xue Bao. 2018 May 20;38(5):520-526. doi: 10.3969/j.issn.1673-4254.2018.05.03.
To investigate the protective effect of exendin-4 against diabetic cardiomyopathy in mice and explore the underlying mechanism.
C57BL/6J mice were randomly divided into normal control group with normal diet and diabetic group with high-fat diet for 4 weeks before streptozotocin injection. The successfully established diabetic mouse models were divided into diabetic group with exendin-4 treatment and diabetic control group for daily treatment with intraperitoneal injection of 1 nmol/kg exendin-4 and saline of equivalent volume for 8 weeks, respectively. The physiological parameters such as blood glucose and body weight were recorded. RT-PCR was used to examine the transcription levels of genes related with myocardial hypertrophy and fibrosis and the genes related with mitochondrial functions including PGC1α, NRF and CytoC. The expressions of oxidative stress markers and Sirt1/PGC1 proteins were measured using Western blotting. and HE staining was used to observe the myocardial structural changes in the mice.
Compared with the normal control mice, the mice in diabetic control group showed significantly increased blood glucose and blood lipid levels (P<0.001), which were obviously improved by Exendin-4 treatment. The expressions of ANP, BNP, TGFβ1, CytoC1 and NOX1 were significantly increased (P<0.05) while Sirt1, PGC1α, NRF and SOD1 expression were markedly decreased in the myocardial tissue of the diabetic mice (P<0.05). Exendin-4 treatment resulted in obviously reduced expressions of ANP, BNP, TGFβ1, CytoC1 and NOX1 (P<0.05) and increased expressions of Sirt1, PGC1α, NRF and SOD1 (P<0.05) in the diabetic mice.
Exendin-4 protects against myocardial injury in diabetic mice by improving mitochondrial function and inhibiting oxidative stress through the Sirt1/PGC1α signaling pathway.
探讨艾塞那肽-4对小鼠糖尿病性心肌病的保护作用,并探究其潜在机制。
将C57BL/6J小鼠随机分为正常饮食的正常对照组和在注射链脲佐菌素前高脂饮食4周的糖尿病组。成功建立的糖尿病小鼠模型再分为接受艾塞那肽-4治疗的糖尿病组和糖尿病对照组,分别每日腹腔注射1 nmol/kg艾塞那肽-4和等量生理盐水,持续8周。记录血糖、体重等生理参数。采用逆转录聚合酶链反应(RT-PCR)检测与心肌肥大、纤维化相关基因以及与线粒体功能相关基因(包括PGC1α、NRF和细胞色素C(CytoC))的转录水平。使用蛋白质免疫印迹法检测氧化应激标志物和Sirt1/PGC1蛋白的表达。并采用苏木精-伊红(HE)染色观察小鼠心肌结构变化。
与正常对照小鼠相比,糖尿病对照组小鼠血糖和血脂水平显著升高(P<0.001),艾塞那肽-4治疗后明显改善。糖尿病小鼠心肌组织中,心房钠尿肽(ANP)、脑钠肽(BNP)、转化生长因子β1(TGFβ1)、细胞色素C1(CytoC1)和NADPH氧化酶1(NOX1)的表达显著增加(P<0.05),而沉默信息调节因子1(Sirt1)、PGC1α、NRF和超氧化物歧化酶1(SOD1)的表达明显降低(P<0.05)。艾塞那肽-4治疗使糖尿病小鼠中ANP、BNP、TGFβ1、CytoC1和NOX1的表达明显降低(P<0.05),Sirt1、PGC1α、NRF和SOD1的表达增加(P<0.05)。
艾塞那肽-4通过改善线粒体功能并通过Sirt1/PGC1α信号通路抑制氧化应激,从而保护糖尿病小鼠免受心肌损伤。